Clostridium difficile infection: Current, forgotten and emerging treatment options

Journal of Comparative Effectiveness Research

Volumn 3, Issue 5, 2014, Pages 547-557

  Drekonja, Dimitri M ^a,b  

^a Minneapolis Veterans Affairs Health Care System   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Clostridium difficile infection; fecal microbiota therapy; fidaxomicin; metronidazole; vancomycin

Indexed keywords

BACITRACIN; BACTERIAL VACCINE; FIDAXOMICIN; FUSIDIC ACID; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PLACEBO; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FECAL MICROBIOTA THERAPY; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; RECURRENT INFECTION; REVIEW; VACCINATION; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; ECONOMICS; FECES; MICROBIOLOGY; MICROFLORA; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COST-BENEFIT ANALYSIS; CROSS INFECTION; FECES; HUMANS; MICROBIOTA; VACCINATION;

EID: 84908464532     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.14.36     Document Type: Review

References (76)

1. Hall IC, OToole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am. J. Dis. Child. 49(49), 390-402 (1935).
2. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-Associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med. 298(10), 531-534 (1978).
3. Larson HE, Price AB, Honour P, Borriello SP. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1(8073), 1063-1066 (1978).
4. Hospital Infection Control PracticesAdvisory Committee. Recommendations for preventing the spread of vancomycin resistance recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. 44(RR-12), 1-13 (1995).
5. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-Associated diarrhoea and colitis. Lancet 2(8358), 1043-1046 (1983).
6. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-Associated diarrhea. Clin. Infect. Dis. 22(5), 813-818 (1996).
7. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br. Med. J. 2(6153), 1667-1669 (1978).
8. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-Associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am. J. Med. 86(1), 15-19 (1989).
9. Young GP, Ward PB, Bayley N, et al. Antibiotic-Associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 89(5), 1038-1045 (1985).
10. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-Associated diarrhoea. J. Antimicrob. Chemother. 54(1), 211-216 (2004).
11. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg. Infect. Dis. 13(9), 1417-1419 (2007).
12. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-Associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353(23), 2442-2449 (2005).
13. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-Associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171(5), 466-472 (2004).
14. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45(3), 302-307 (2007).
15. Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-Associated diarrhea. Clin. Infect. Dis. 43(5), 547-552 (2006).
16. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin. Infect. Dis. 48(4), e41-e46 (2009).
17. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis. 43(4), 421-427 (2006).
18. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection N. Engl. J. Med. 364(5), 422-431 (2011).
19. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-Associated Clostridium difficile infection and of healthcare-Associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect. Control Hosp. Epidemiol. 32(4), 387-390 (2011).
20. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 30(1), 57-66 (2009).
21. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of and risk factors for community-Associated Clostridium difficile infection: a nested case-control study. BMC Infect. Dis. 11, 194 (2011).
22. Eyre DW, Cule ML, Wilson DJ, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N. Engl. J. Med. 369(13), 1195-1205 (2013).
23. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J. Infect. 58(6), 403-410 (2009).
24. Drekonja DM, Amundson WH, Decarolis DD, Kuskowski MA, Lederle FA, Johnson JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am. J. Med. 124(11), 1081.e1-1081.e7 (2011).
25. CDC. Antibiotic Resistance Threats in the United States, 2013 (2013). www.cdc.gov/drugresistance/threat-report-2013
26. Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-Associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am. J. Gastroenterol. 102(12), 2781-2788 (2007).
27. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin. Infect. Dis. 48(12), 1732-1735 (2009).
28. Drekonja DM, Butler M, Macdonald R, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann. Intern. Med. 155(12), 839-847 (2011)
29. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann. Intern. Med. 117(4), 297-302 (1992
30. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-Associated disease. Antimicrob. Agents Chemother. 52(7), 2403-2406 (2008).
31. Bishara J, Wattad M, Paul M. Vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea. Clin. Infect. Dis. 45(12), 1646-1647 (2007).
32. Huggan PJ, Murdoch DR. Vancomycin therapy for severe Clostridium difficile-Associated diarrhea. Clin. Infect. Dis. 45(12), 1647-1648 (2007).
33. Lawrence SJ, Dubberke ER, Johnson S, Gerding DN. Clostridium difficile-Associated disease treatment response depends on definition of cure. Clin. Infect. Dis. 45(12), 1648; author reply 1649-1651 (2007).
34. Pakyz AL, Carroll NV, Harpe SE, Oinonen M, Polk RE. Increase in use of vancomycin for Clostridium difficile infection in US hospitals. Infect. Control Hosp. Epidemiol. 31(8), 867-868 (2010).
35. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31(5), 431-455 (2010).
36. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1-12 (2009).
37. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin. Infect. Dis. 57(4), 555-561 (2013).
38. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea: a randomized double-blind trial. Arch. Intern. Med. 146(6), 1101-1104 (1986).
39. De Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-Associated diarrhea. Antimicrob. Agents Chemother. 36(10), 2192-2196 (1992).
40. Wilcox MH. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin. Microbiol. Infect. 13(10), 949-952 (2007).
41. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-Analysis. Lancet Infect. Dis. 11(11), 834-844 (2011).
42. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362(3), 197-205 (2010).
43. Valerio M, Pedromingo M, Munoz P, et al. Potential protective role of linezolid against Clostridium difficile infection. Int. J. Antimicrob. Agents 39(5), 414-419 (2012).
44. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin. Infect. Dis. 55(5), 615-620 (2012).
45. Ohoro JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 42(1), 43-59 (2014).
46. Surawicz CM, Mcfarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis. 31(4), 1012-1017 (2000).
47. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin. Infect. Dis. 55 (Suppl. 2), S154-S161 (2012).
48. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile N. Engl. J. Med. 368(5), 407-415 (2013).
49. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-Associated disease in Quebec, Canada. Clin. Infect. Dis. 42(6), 758-764 (2006).
50. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-Associated pseudomembranous colitis. Am. J. Gastroenterol. 80(11), 867-868 (1985).
51. Mcfarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 97(7), 1769-1775 (2002).
52. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-Associated diarrhoea: a double-blind, placebo-controlled trial. Scand. J. Infect. Dis. 35(6-7), 365-367 (2003).
53. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-Associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 44(6), 846-848 (2007).
54. Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 15(6), 290-291 (2009).
55. Mattila E, Anttila VJ, Broas M, et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-Associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand. J. Infect. Dis. 40(9), 702-708 (2008).
56. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J. Clin. Gastroenterol. 38(6), 475-483 (2004).
57. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44(5), 854-859 (1958).
58. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36(5), 580-585 (2003).
59. Kelly CR, De Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J. Clin. Gastroenterol. 46(2), 145-149 (2012).
60. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107(5), 761-767 (2012).
61. Silverman MS, Davis I, Pillai DR. Success of self-Administered home fecal transplantation for chronic Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 8(5), 471-473 (2010).
62. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch. Intern. Med. 172(2), 191-193 (2012).
63. Dutta SK, Girotra M, Garg S, et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin. Gastroenterol. Hepatol. doi:10.1016/j.cgh.2013.12.032 (2014) (Epub ahead of print).
64. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin. Infect. Dis. 58(11), 1515-1522 (2014).
65. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53(10), 994-1002 (2011).
66. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J. Clin. Gastroenterol. 48(8), 693-702 (2014).
67. Moore T, Rodriguez A, Bakken JS. Fecal microbiota transplantation: a practical update for the infectious disease specialist. Clin. Infect. Dis. 58(4), 541-545 (2014).
68. Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin. Infect. Dis. 55(12), 1652-1658 (2012).
69. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: RePOOPulating the gut. Microbiome 1(1), 3 (2013).
70. Shaughnessy MK, Amundson WH, Kuskowski MA, Decarolis DD, Johnson JR, Drekonja DM. Unnecessary antimicrobial use in patients with current or recent Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 34(2), 109-116 (2013).
71. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch. Intern. Med. 170(9), 772-778 (2010).
72. Gerding DN. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov. Med. 13(68), 75-83 (2012).
73. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect. Immun. 69(2), 988-995 (2001).
74. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonisation with non-Toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int. J. Antimicrob. Agents 33(Suppl. 1), S46-S50 (2009).
75. Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum. Vaccin. Immunother. 10(6), doi:10.4161/hv.28428 (2014) (Epub ahead of print).
76. Brouwer MS, Roberts AP, Hussain H, Williams RJ, Allan E, Mullany P. Horizontal gene transfer converts non-Toxigenic Clostridium difficile strains into toxin producers. Nat. Commun. 4, 2601 (2013